US Patent

US7659291 — Methods of treatment with pre-mixed, ready-to-use pharmaceutical compositions

Method of Use · Assigned to EKR Therapeutics Inc · Expires 2027-04-18 · 1y remaining

Vulnerability score 85/100 Vulnerable — likely target for IPR or design-around

What this patent protects

This patent protects methods of treating cardiovascular and cerebrovascular conditions using pre-mixed, ready-to-use pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt.

USPTO Abstract

Provided herein are ready-to-use premixed pharmaceutical compositions of nicardipine or a pharmaceutically acceptable salt and methods for use in treating cardiovascular and cerebrovascular conditions.

Drugs covered by this patent

nicardipine-hydrochloride (NICARDIPINE HYDROCHLORIDE)

FDA Patent Use Codes

When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.

Code	Description	Drug
`U-1029`	—	nicardipine-hydrochloride
`U-1029`	—	nicardipine-hydrochloride
`U-1029`	—	nicardipine-hydrochloride
`U-1029`	—	nicardipine-hydrochloride

Patent Metadata

Patent number: US7659291
Jurisdiction: US
Classification: Method of Use
Expires: 2027-04-18
Drug substance claim: No
Drug product claim: No
Assignee: EKR Therapeutics Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.